Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neurodermatitis Clear all
Completed Phase 3 Interventional Results available

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

NCT04202679
View directory record Official record
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 22, 2026, 5:11 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

NCT06687980
View directory record Official record
Conditions
Lichen Simplex Chronicus
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Anaheim, California • Fremont, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04501679
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jul 22, 2026, 5:11 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

NCT06687967
View directory record Official record
Conditions
Lichen Simplex Chronicus
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Clarkston, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

NCT01912391
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Selegiline, Placebo (for Selegiline)
Drug
Lead sponsor
Mood and Anxiety Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Jul 22, 2026, 5:11 PM EDT
Not listed Not applicable Interventional

Dapsone Prurigo Study

NCT01870050
View directory record Official record
Conditions
Lichen Simples Chronicus and Prurigo
Interventions
Dapsone gel - verum
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jul 22, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04501666
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Nemolizumab 30 mg, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jul 22, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634
View directory record Official record
Conditions
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions
KPL-716, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 22, 2026, 5:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
View directory record Official record
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jul 22, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

NCT04183335
View directory record Official record
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jul 22, 2026, 5:11 PM EDT